RxDoctor Payments Data

Amit Trehan, MD

Gastroenterology · Amarillo, TXNPI 1952308108

Payments from drug & device makers

$7,615in general payments, 2019–2025

Across 344 payments — averaging $22.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Takeda Pharmaceuticals U.S.A., Inc.$784
  • Pfizer$343
  • Gilead$310
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$244
  • Intercept Pharmaceuticals, Inc.$180
  • plus $2K from 21 others

What the payments were for

  • Speaking & faculty fees$1,60021%
  • Food & beverage$6,01579%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,615 in reported general payments places this provider in the 65th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$151,117
Medicare patients
617
Services billed
1,142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide115$96,903
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C86$12,242
Colestipol Hcl162$9,970
ClenpiqSod Picosulf/Mag Ox/Citric Ac53$8,992
Dexlansoprazole DrDexlansoprazole23$6,366
Omeprazole398$6,321
Budesonide DrBudesonide30$4,162
DexilantDexlansoprazole11$3,846
Pantoprazole Sodium331$3,260
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl189$3,163
Lubiprostone34$2,512
CholestyramineCholestyramine (With Sugar)11$1,650
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates25$1,457
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl87$1,445
Ursodiol13$1,425

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$3,964$96,903115 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$244$12,24286 claims
Ferring Pharmaceuticals Inc.Clenpiq$139$8,99253 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$784$3,84611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →